Metastatic Pancreatic Ductal Adenocarcinoma Clinical Trials

78 clinical trials for Metastatic Pancreatic Ductal Adenocarcinoma across international registries, including 22 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE2
• Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors — RECRUITING · PHASE1
• Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors — RECRUITING · PHASE1
• Hellenic Evaluation of the Long-Term Safety and Efficacy of NalIriFOx as a 1st-line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — RECRUITING
• A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue — RECRUITING · PHASE2
• Personalized Peptide Vaccine in Treating Patients With Advanced Pancreatic Cancer or Colorectal Cancer — RECRUITING · PHASE1
• Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE1
• BBO-11818 in Adult Subjects With KRAS Mutant Cancer — RECRUITING · PHASE1
• Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — RECRUITING · PHASE3
• ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE1
• MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE1
• OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE1
• Targeted Pathway Inhibition in Patients With Pancreatic Cancer — RECRUITING · PHASE1
• SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells — RECRUITING · PHASE1
• Hyperpolarized 13C MRI to Predict Response in Pancreatic Cancer — RECRUITING
• A PHASE 2B/3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PONSEGROMAB (PF-06946860) COMPARED WITH PLACEBO BOTH WITH BACKGROUND FIRST-LINE CHEMOTHERAPY IN ADULT PARTICIPANTS WITH CACHEXIA AND METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA — RECRUITING · PHASE2
• Utility of ctDNA in Early Switch of First-line mFOLFIRINOX in Metastatic Pancreatic Ductal Adenocarcinoma — RECRUITING · PHASE2
• The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation — RECRUITING · PHASE2
• MOUNTAINTAP-30: A RANDOMIZED, PHASE 2/3 STUDY COMPARING BMS-986504 IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE VERSUS PLACEBO IN COMBINATION WITH NAB-PACLITAXEL AND GEMCITABINE IN PARTICIPANTS WITH UNTREATED METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA HARBORING HOMOZYGOUS MTAP DELETION — RECRUITING · PHASE2
• A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC) — RECRUITING · PHASE2
• A RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, MULTICENTER, PHASE 3 TRIAL OF QUEMLICLUSTAT AND CHEMOTHERAPY VERSUS PLACEBO AND CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAIVE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA — RECRUITING · PHASE3
• A PHASE II OPEN-LABEL, MULTI-CENTER STUDY OF MEDI4736 EVALUATED AS SINGLE AGENT OR IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA — RECRUITING · PHASE2
• A Study in a Type of Pancreatic Cancer that has Spread Beyond the Pancreas — COMPLETED · PHASE2
• PET Imaging Using 64Cu-Tz-SarAr and hu5B1-TCO in People With Pancreatic, Colorectal, Bladder Cancer or Cancers With Elevated CA19.9 — WITHDRAWN · PHASE1
• A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• RASolute 302: A Phase 3 Multicenter, Open-label, Randomized Study of RMC-6236 versus Investigator’s Choice of Standard of Care Therapy in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — TERMINATED · PHASE3
• CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer — SUSPENDED · PHASE1
• Randomized phase 2 study of Valproic acid combinEd with Simvastatin and gemcitabine/nab-paclitaxel-based regimens in untreated metastatic Pancreatic Adenocarcinoma patients (The VESPA trial) — TERMINATED · PHASE2
• Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE3
• Efficacy and Safety of Serplulimab in Combination With Bevacizumab and FOLFIRINOX or NALIRIFOX as Second-Line Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — NOT_YET_RECRUITING · PHASE2
• A Cancer Research UK Phase II open label trial in participants with metastatic pancreatic ductal adenocarcinoma of ginisortamab given intravenously I) with first-line standard of care nab-paclitaxel and gemcitabine, or II) in combination with MEK inhibitor maintenance therapy — TERMINATED · PHASE2
• A Study Comparing Whole-Body Heat Treatment Plus Systemic Therapy to Systemic Therapy Alone, for Advanced Pancreatic Cancer — NOT_YET_RECRUITING · PHASE2
• Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma — TERMINATED · PHASE1
• A Phase I open label followed by a Phase II randomized, controlled study to assess the efficacy and safety of ABTL0812 in combination with FOLFIRINOX for first-line treatment of metastatic pancreatic cancer — TERMINATED · PHASE2
• A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer — COMPLETED · PHASE2
• Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma — NOT_YET_RECRUITING · PHASE1
• Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations — NOT_YET_RECRUITING · PHASE1
• Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2 — COMPLETED · PHASE3
• PHASE 2/3 OPEN LABEL RANDOMIZED STUDY OF TELISOTUZUMAB ADIZUTECAN IN COMBINATION WITH FOLFOX COMPARED TO STANDARD OF CARE IN SUBJECTS WITH FIRST- LINE METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA - ANDROMETA-PDAC-288 — NOT_YET_RECRUITING · PHASE2
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal Adenocarcinoma — COMPLETED · PHASE2
• A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies — COMPLETED · PHASE1
• Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal Adenocarcinoma — NOT_YET_RECRUITING · PHASE1
• AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — NOT_YET_RECRUITING · PHASE3
• Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy — ACTIVE_NOT_RECRUITING · PHASE2
• BXCL701 and Pembrolizumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE2
• STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma — WITHDRAWN · PHASE1
• PANOVA-4: Pilot, Single arm Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) — OTHER · PHASE3
• Phase I Study of Cosibelimab and Balixafortide in Metastatic Pancreatic Ductal Adenocarcinoma — NOT_YET_RECRUITING · PHASE1

Refine this search